Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger
Renovaro Inc. (NASDAQ:RENB) stated that the Delaware Court of Chancery has granted an expedited trial to its action against Predictive Oncology Inc. (NASDAQ:POAI), which was filed on May 9, 2025.
A laboratory technician researching a sample of cells in a biotechnology laboratory.
A binding merger agreement signed on January 1, 2025, which called for Predictive Oncology to merge into Renovaro Inc. (NASDAQ:RENB) in exchange for a new class of preferred stock, is being enforced in this action (No. 2025-0509). According to Renovaro's complaint, POAI violated the terms of exclusivity and good faith by launching a $545,000 public securities offering on February 19, 2025, and then making an attempt to unilaterally end the agreement on April 3, 2025. Renovaro Inc. (NASDAQ:RENB) is seeking damages, injunctive relief, and specific performance.
The case focuses on a Letter Agreement that caused POAI's share price to rise by more than 50% and was made public in a January 6, 2025, Form 8-K. Renovaro Inc. (NASDAQ:RENB) asserts that POAI's activities, which breached the agreed-upon confidentiality and did not participate in substantive negotiations toward a final agreement, violated the conditions of the merger.
Renovaro Inc. (NASDAQ:RENB) is a TechBio business that specializes in cancer treatments, drug development, and diagnostics. Among its subsidiaries are BioSymetrics (AI for precision neurology), RenovaroBio (cell-gene immunotherapy), and RenovaroCube (AI-driven diagnostics and drug development). Concerns about shareholder value and legal attempts to uphold M&A agreements are brought to light in this case.
While we acknowledge the potential of RENB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RENB and that has 100x upside potential, check out our report about this
READ NEXT: and .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Report: Ratepayers will foot the bill for power transmission project
Jun. 7—MORGANTOWN — Depending on who you ask, NextEra's MidAtlantic Resiliency Link transmission project will either take advantage of West Virginia ratepayers and countryside to power up data centers in Virginia — or it'll be an economic boon to the Mountain State, generating hundreds of jobs and hundreds of millions in tax revenue. The Institute for Energy Economics and Financial Analysis is solidly in the former camp. In a May report compiled by Cathy Kunkel, "West Virginia Ratepayers Footing the Bill for Infrastructure Build Out, " the IEEFA makes the claim that two power transmission projects slated to run through West Virginia on their way to northern Virginia will cost West Virginia ratepayers more than $440 million over the next 40 years despite the demand being almost entirely attributable to data centers. A data center is a physical room, building or facility that houses IT infrastructure for building, running and delivering online applications and services, according to IBM. One of those projects, a billion-dollar transmission line that includes NextEra's MidAtlantic Resiliency Link, is looking at parts of Monongalia and Preston counties as a route for the 105-mile "major highway " of 500-kilovolt overhead transmission lines running from Greene County to Frederick County, Va. The project will require a 200-foot right of way along its entire length and terminate in northern Virginia, which already has the highest concentration of data centers in the world. The power-hungry facilities are being built at an increasingly rapid pace. According to the IEEFA, electricity demand across the 13-state territory under grid operator PJM Interconnection remained relatively flat for nearly two decades. That's changed in the last three years due almost exclusively to the rise of data centers. As of 2023, data centers accounted for more than one-quarter of the electricity consumption in the state of Virginia, based on data presented by IEEFA. One large data center, the report states, can draw as much power as a city. The think tank says the traditional method of cost allocation — spreading the cost of capital investments across the customer base — isn't equitable when capital improvements are being constructed to feed a single customer or a very small group of customers. "As this report explains in greater detail, traditional methods of cost allocation for major new transmission projects in PJM have not yet been reconsidered in light of the new challenges posed by data center demand growth." The Dominion Post reached out to NextEra with three questions: What benefit will West Virginians receive in exchange for the large transmission lines running through rural parts of the state ? What percentage of the power being pulled from Pennsylvania to Virginia will support data centers ? Will residential ratepayers end up subsidizing the construction of this project in any way ? "The MidAtlantic Resiliency Link is one of the transmission projects PJM selected to enhance grid reliability for customers locally and across the region, " NextEra replied in a statement. "While it's part of a regional solution, the local benefits are significant. The [MARL ] would create hundreds of construction and support jobs, which will, in turn, drive significant investment in the local economy, growing existing businesses and attracting new businesses. Importantly, West Virginia is projected to receive an estimated $150-$400 million in taxes over the 40-year life of this project, depending on the length and route of the final transmission line. The [MARL ] would help drive economic development throughout the state." But before any of that comes to pass, a route must be finalized. Some residents in Monongalia and Preston counties have started voicing concerns about the possibility of having the transmission lines run through or near their properties. Property owners in rural, wooded and farming areas fear they'll be forced to give up ground through eminent domain should their land fall in the chosen path. On May 29, the Preston County Commission passed a resolution opposing the MARL project as currently proposed and urging state and federal regulators, as well as NextEra, to halt development of the project through Preston County. Asked whether a similar resolution might come out of Monongalia County, Commissioner Sean Sikora said the commission is doing its due diligence and has reached out to Preston County for a copy of the resolution—but isn't ready to take any kind of public stance on the matter. NextEra has conducted a series of open house-style public meetings in recent weeks to discuss, among other things, the potential routes, and intends to make its choice known to the various state public service commissions this fall. According to the current timeline, the project is to be completed by the end of 2031.
Yahoo
17 minutes ago
- Yahoo
Shuffle Board: Better Cotton Names Nonprofit Exec Nick Weatherill CEO
Global sustainability initiative Better Cotton announced Nick Weatherill as its next chief executive officer. Weatherill replaces Alan McClay, who announced his decision to step down last December after leading the organization since 2015. Weatherill previously served as executive director of the International Cocoa Initiative and brings ample experience promoting sustainability and human rights in global supply chains. Atlanta-based company Brrr has named David Ludd as vice president of sales and marketing. Ludd joined the company last year and has over three decades of experience in apparel sales and marketing. He most recently served as Coolcore's chief global sales and marketing officer and previously held senior leadership roles at Converse, Timberland, Nike and Levi Strauss & Co. More from Sourcing Journal Nike's 3D-Printed Air Max Set to Release This Summer StockX Says It Weeded Out Nearly $10 Million Worth of Counterfeit Sneakers Last Year Dr. Martens' Stock Soars as CEO Implements New Strategic Plan Following 'Year of Stabilization' French multinational luxury goods company Dior confirmed that Loewe's former creative director, Jonathan Anderson, will lead fashion for the LVMH-owned label. He'll lead all three Dior collections as creative director of women's, men's and haute couture—marking the first time the house has seen one creative vision since founder Christian Dior helmed the triptych role. Anderson succeeds Maria Grazia Chiuri, who stepped down last month after a nine-year run as Dior's first woman (ever) to lead its women's collection. American denim and sportswear brand True Religion has promoted Kristen D'Arcy and Tina Blake, as the brand expects annual sales to top $450 million this year, according to SJ's sister publication, WWD. D'Arcy was named True Religion's first-ever chief marketing officer in 2023. Now, her role has expanded to CMO and head of digital growth. In addition to leading the marketing team, D'Arcy's will also oversee the e-commerce, analytics, and customer service teams. Tina Blake has been promoted to creative director; SVP design, merchandising and brand image. She joined True Religion in 2022 and most recently served as senior vice president of men's and women's design and brand image. In this role, Blake will oversee the entire merchandising organization as well as her design and brand image leadership responsibilities. Athleticwear giant Nike has named Michael Gonda as chief communications officer, effective July 7. In this role, Gonda will oversee the company's global communications operations and strategy, including corporate and brand reputation, storytelling, issues management and employee engagement. Gonda previously held various leadership roles at McDonald's Corporation, most recently serving as its chief impact officer for North America. British boot brand Dr. Martens has named Carla Murphy as chief brand officer, effective July 1. In this role, Murphy will be responsible for the company's brand strategy and creative direction, as well as overseeing the company's global product, marketing and sustainability teams. She will report to former BSO and current CEO, Ije Nwokorie. Aspen, Colorado-based ski company Sport Obermeyer has announced a new leadership team in preparation for its 2026 rebranding effort. Former Mammut and X-Bionic leader Kris Kuster was named chief executive officer, Kalin Tegman has been promoted to director of sales, and Lilly McSwain has been named customer service manager. Reinforcing the brand's commitment to best-in-class client relationships and service. Founder Klaus Obermeyer will remain an active board member as the oldest living company president at 105 years old. Utah-based footwear brand Kizik has named former Nike exec Gareth Hosford as chief executive officer. In this role, he will work to scale innovation, reach and opportunities for the brand as it continues to transition from a DTC business model to an omni-channel effort. Hosford succeeds Monte Deere, who has held the role since 2019, will continue to serve on the board of Kizik (and its parent company, HandsFree Labs) as to advise on the company's licensing arm of the business. StockX has named Daniel De Jesus Krueger as vice president and head of creative. He will lead the global creative direction of the sneaker resale marketplace, encompassing brand design, imagery and storytelling. Krueger joins StockX from Fulwell Entertainment, an entertainment group founded by athlete LeBron James and sports marketer Maverick Carter, formerly known as SpringHill Company. California surf-and-skate retailer Pacsun has named Rachel Donahue as vice president of human resources. She will oversee all aspects of human resources at Pacsun, including talent development, organizational effectiveness and employee engagement. Donahue brings over two decades of experience leading people strategy across retail and fashion brands. She most recently served as Aritzia's vice president, people and culture, responsible for talent management, executive development and shaping the company culture. Her prior experience includes senior HR roles at Saks, Tory Burch and Macy's. Autonomous delivery network Arrive AI has appointed Laurie Tucker to its board of directors. Tucker, a former senior vice president of marketing at FedEx and an experienced board member, will serve as head of Arrive AI's compensation committee.
Yahoo
23 minutes ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
